Linear pharmacokinetics of micafungin and its active metabolites in Japanese pediatric patients with fungal infections

Kenji Tabata, Masataka Katashima, Akio Kawamura, Yusuke Tanigawara, Keisuke Sunagawa

研究成果: Article査読

30 被引用数 (Scopus)

抄録

The objective of this study was to propose the appropriate dosage regimen of micafungin for pediatric use, considering the effects of dose-linearity, age and other cofactors on the pharmacokinetics. Pharmacokinetic analysis of micafungin and its active metabolites (M1 and M2) after intravenous infusion at doses of 1 to 3 mg/kg was conducted for 19 Japanese pediatric patients (3 infants, 7 toddlers, and 9 pupils) with deep mycosis caused by either Aspergillus or Candida species. One patient was given the maximum dose of 6 mg/kg. The Cmax of micafungin increased in proportion to the dose. The mean values (S.D.) were 5.03 (2.33), 10.25 (4.45), 14.8 (5.52) and 21.1 μg/ml at 1, 2 , 3 and 6 mg/kg, respectively. These parameters were comparable to those seen in adults when the parameter was normalized by body weight. The elimination half life (t1/2) of micafungin over the dose range was apparently constant with the value of 13.1 h. There was no difference between the age groups observed. In fact, the metabolite concentrations were almost the same as those obtained for non-pediatric patients. Thus, micafungin showed the same dose-proportional pharmacokinetics in pediatric patients as it did in adults. No age dependent pharmacokinetics were observed in this study. It was concluded that the body weight adjustment was adequate for the treatment of micafungin in pediatric patients.

本文言語English
ページ(範囲)1706-1711
ページ数6
ジャーナルBiological and Pharmaceutical Bulletin
29
8
DOI
出版ステータスPublished - 2006

ASJC Scopus subject areas

  • 薬理学
  • 薬科学

フィンガープリント

「Linear pharmacokinetics of micafungin and its active metabolites in Japanese pediatric patients with fungal infections」の研究トピックを掘り下げます。これらがまとまってユニークなフィンガープリントを構成します。

引用スタイル